CDKN2A and anaplastic meningioma: To address this issue, we analyzed the accuracy of routinely used molecular methods - DNA methylation profiling, molecular inversion probe (MIP) analysis, targeted next-generation DNA panel sequencing (NGS), and fluorescence in situ hybridization (FISH) - in determining the genetic status of CDKN2A and MTAP, and compared the genetic data with the surrogate protein expression of p16 and MTAP in nine cases of anaplastic meningiomas.